[{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"$8.2 million","newsHeadline":"Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from Botanix","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Botanix Pharma
Sofdra (sofpironium) works by inhibiting M3 muscarinic receptors in eccrine glands. It is approved for the treatment of primary axillary hyperhidrosis in patients ages 9 and older.
Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).